

主管：
湖南省卫生健康委员会

主办：
湖南省肿瘤医院

学术顾问：
孙燕 周宏灏 甄永苏
马军 王忠民 杨汉煜
梅建明 霍仕文

编委会主任：
向华

名誉主编：
任华益

主编：
王静

副主编：
董晓荣 廖前进 刘昭前
欧阳取长 向阳 杨农
杨小平 张会来 周辉

编辑部主任：
王静

编辑：
董珊珊 房超 李征
王娟 于静

责任编辑：
刘颖

出版：
《肿瘤药学》编辑部

国内发行：
湖南省报刊发行局
邮发代号：42-391

国外发行：
中国国际图书贸易集团有限公司
(北京399信箱, 100048)
代号：BM2809

目次

临床研究管理及伦理

肿瘤受试者对以患者为中心的药物临床试验的参与意愿及其影响因素调查	吴清, 孙超, 吴大维, 等	653
抗肿瘤药物临床试验中心药房信息化管理模式的建立与应用探讨	唐琪, 谭英红, 龚倩	662
抗肿瘤药物临床试验中方案违背现状及原因分析	金艳, 于杨	666
单中心抗肿瘤药物 I 期临床试验中研究参与者筛选失败原因分析及对策探讨	苏禾, 李慧, 张子易, 等	673

文献解读

瑞波西利联合非甾体芳香化酶抑制剂辅助治疗 HR+/HER2-早期乳腺癌: III 期 NATALEE 研究解析	刘莉萍, 欧阳取长	679
---	-----------	-----

综述

HER2 阳性乳腺癌抗 HER2 治疗研究进展	向泓雨, 刘荫华	686
I A 期肺腺癌临床高危因素及术后辅助治疗研究进展	陈火育, 程磊, 彭东阁, 等	695
肾细胞癌分子靶向治疗耐药性研究进展	廉珂, 王渤文, 倪少滨	702
靶向 Trop2 CAR-T 治疗肺腺癌的研究进展	蔡新培, 高锦莉, 徐芹芹	707
铁蛋白作为药物载体在肿瘤治疗中的应用进展	潘文杰, 石峰	716

临床研究

扶正祛邪方联合 EGFR-TKI 治疗晚期肺腺癌的临床研究	许荣忠, 李雁, 张玲, 等	723
阿替利珠单抗联合贝伐珠单抗治疗 TACE 抵抗中晚期肝细胞癌的疗效及安全性分析	郭栋, 张锋利, 郑伟	731
抗肿瘤药物治疗的晚期非小细胞肺癌患者生存预后分析	郑克澳, 郝志英, 李方钰, 等	738
中晚期原发性肝细胞癌 ICIs 相关不良反应风险预测模型的构建与验证	宋发祥, 郭社民, 王静	747

药品安全数据研究

基于 FAERS 数据库的瑞派替尼不良事件信号挖掘与分析	许毓颖, 郑燕玲, 潘伟萍	753
------------------------------	---------------	-----

中国标准连续出版物号:

ISSN 2095-1264
CN 43-1507/R

商标注册证号:

6125707

印刷:

长沙芙蓉印务广告有限公司

邮购:

《肿瘤药学》编辑部(长沙市岳麓区咸嘉湖路582号湖南省肿瘤医院,邮编:410013)

(本刊发行部全年办理补订手续)

电话:

0731-89762609

网址:

<http://www.zgzlyx.com>

中国知网优先数字出版网址:

<http://www.cnki.net>

邮箱:

zgzlyx2011@163.com

微信服务号:

肿瘤药学杂志

定价:

每本30元,全年180元

出版日期:

2024年12月28日

期刊基本参数:

CN 43-1507/R*2011*B*A4*128*
ZH*P*¥30.00*19*2024-12

药学服务

临床药师参与1例乳腺癌患者颈内静脉血栓抗凝治疗的案例分析

..... 张 艺, 戎佩佩, 解吉奕 760

晚期顽固性癌痛患儿多种模式融合的药学服务实践

..... 尚飞能, 宋 芳, 徐家忠, 等 764

病例报道

纳武利尤单抗致中毒性表皮坏死松解症1例

..... 顾融融, 陈 玲, 朱秋燕, 等 769

盐酸多柔比星脂质体所致间擦疹型IV级手足综合征合并感染1例病例报道并文献复习

..... 石 坚, 谢钟芸, 杨海峰 774

本刊版权归《肿瘤药学》编辑部所有,如有印刷质量问题请向编辑部申请更换。

ANTI-TUMOR PHARMACY

Bimonthly

Established in February 2011

Volume 14 Number 6 December 2024

Administrative Office:

Health Commission of Hunan Province

Sponsored by:

Hunan Cancer Hospital

Academic Advisor:

SUN Yan, ZHOU Honghao,
ZHEN Yongsu, MA Jun,
WANG Zhongmin, YANG Hanyu,
MEI Jianming, HUO Shiwen

Chief of Editorial Board:

XIANG Hua

Honorary Editor-in-Chief:

REN Huayi

Editor-in-Chief:

WANG Jing

Deputy Editor-in-Chief:

DONG Xiaorong, LIAO Qianjin,
LIU Zhaoqian, OUYANG Quchang,
XIANG Yang, YANG Nong,
YANG Xiaoping, ZHANG Huilai,
ZHOU Hui

Director of Editorial Department:

WANG Jing

Editor:

DONG Shanshan, FANG Chao,
LI Zheng, WANG Juan, YU Jing

Editor in Charge:

LIU Ying

Publication:

Editorial Department of *Anti-tumor
Pharmacy*

Domestic Distributor:

Hunan Bureau for Distribution of
Newspaper and Periodicals
Code No. 42-391

Overseas Distributor:

China International Book Trading
Corporation (P.O. Box 399, Beijing,
100048, China)
Code No. BM2809

CONTENTS

Clinical Research Management and Ethics

- A survey of cancer subjects' willingness to participate in patient-centric clinical trials and their influencing factors
..... WU Qing, SUN Chao, WU Dawei, et al. 653
- Establishment and application of information management model for central pharmacy of anti-tumor clinical trial
..... TANG Qi, TAN Yinghong, GONG Qian 662
- Analysis on the current situation and causes of protocol deviations in clinical trials of anti-tumor drugs
..... JIN Yan, YU Yang 666
- Analysis on the reasons and countermeasures for participant screening failure in single-centre phase I clinical trials of anti-tumor drugs
..... SU He, LI Hui, ZHANG Ziyi, et al. 673

Literature Interpretation

- Ribociclib plus non-steroidal aromatase inhibitor as adjuvant treatment in HR+/HER2- early breast cancer: interpretation of the phase III NATALEE study
..... LIU Liping, OUYANG Quchang 679

Review

- Advances in anti-HER2 targeted therapy for HER2-positive breast cancer
..... XIANG Hongyu, LIU Yinhua 686
- A review on clinical high-risk factors and postoperative adjuvant therapy in stage I A lung adenocarcinoma
..... CHEN Huoyu, CHENG Lei, PENG Dongge, et al. 695
- Progress in molecular targeted therapy resistance of renal cell carcinoma
..... LIAN Ke, WANG Bowen, NI Shaobin 702
- Research progress of Trop2-targeted CAR-T in the treatment of lung adenocarcinoma
..... CAI Xinpei, GAO Jinli, XU Qinqin 707
- Progress in the application of ferritin as a drug carrier in tumor treatment
..... PAN Wenjie, SHI Feng 716

Clinical Research

- Clinical study of Fuzheng Quxie Formula combined with EGFR-TKI in the treatment of advanced lung adenocarcinoma
..... XU Rongzhong, LI Yan, ZHANG Ling, et al. 723
- Efficacy and safety analysis of atezolizumab combined with bevacizumab in the treatment of TACE-resistant advanced hepatocellular carcinoma
..... GUO Dong, ZHANG Fengli, ZHENG Wei 731
- Survival prognosis of patients with advanced non-small cell lung cancer treated with anti-tumor drugs
..... ZHENG Ke'ao, HAO Zhiying, LI Fangyu, et al. 738

China Standard Serial Numbering:

ISSN 2095-1264
CN 43-1507/R

Trademark Registration:

6125707

Printing:

Changsha Fuyin Printing and Advertising Co., Ltd.

Post Address:

Editorial Department of *Anti-tumor Pharmacy* (No.582 Xianjiahu Road, Changsha, Hunan, China, 410013)

Tel: 0731-89762609

Website: <http://www.zgzlyx.com>

Online First: <http://www.cnki.net>

E-mail: zgzlyx2011@163.com

WeChat Service Account:

AntiTumorPharmacy

Price: ¥30/Issue, ¥180/Year

Publishing Date:

Dec. 28, 2024

Basic Information of the Journal:

CN 43-1507/R*2011*B*A4*128* ZH*P*
¥30.00*19*2024-12

Construction and verification of risk prediction model for ICIs-related adverse events of advanced primary hepatocellular carcinoma
..... SONG Faxiang, GUO Shemin, WANG Jing 747

Drug Safety Data Research

Signal mining and analysis of adverse events of ripretinib based on FAERS database
..... XU Yuying, ZHENG Yanling, PAN Weiping 753

Pharmacy Service

Analysis on the clinical pharmacists' participation in the anticoagulant treatment of internal jugular vein thrombosis in a breast cancer patient
..... ZHANG Yi, RONG Peipei, XIE Jiyi 760

The practice of pharmaceutical care with multi-mode integration in children with advanced intractable cancer pain
..... SHANG Feineng, SONG Fang, XU Jiazhong, et al. 764

Case Report

A case report of nivolumab-associated toxic epidermal necrolysis
..... GU Rongrong, CHEN Ling, ZHU Qiuyan, et al. 769

Grade IV intertrigo-like hand-foot syndrome caused by doxorubicin hydrochloride liposome complicated with infection: a case report and worldwide literature review
..... SHI Jian, XIE Zhongyun, YANG Haifeng 774

• 特别声明 •

本刊作者文责自负，稿件一经采用，该文的复制权、发行权、信息网络传播权、汇编权等相关权利视为自动转让给本刊。本刊有权将上述权利转授给收录本刊的数据库，如作者不同意文章被转录，请来稿时注明，本刊将做适当处理。